Video

Mabion Capacity Update February 2024: Large Molecule

Source: Mabion

Mabion, a biologics CDMO with end-to-end services focusing on recombinant proteins development and production will showcase their new installations in upstream development, new bioreactors, as well as downstream development and fill&finish. This state of the art EU-GMP certified facility is staffed by a team of 250 professionals and as of 2023 is focused solely on providing CDMO services to its clients. Capacity is now available and team is excited to engage in new projects.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development

Please tell us more about you so that we can customize our newsletters to your specific interests: